|
| 2015 n (%) | 2016 n (%) | 2017 n (%) | ||||
| Cases | Public | Private | Public | Private | Public | Private | |
| New | 1692 (82) | 357 (17) | 2648 (83) | 536 (17) | 2677 (80) | 630 (19) | |
| Relapse | 13 (81) | 4 (0.7) | 44 (78) | 17 (2.6) | 28 (53) | 17 (32) | |
| Treatment after failure (TAF) | 2 (12.5) | 0 | 12 (21) |
| 6 (11) | 0 | |
| Lost to follow up (TAD) | 1 (6.25) | 0 |
|
| 0 | 0 | |
| Gender |
|
|
|
|
|
| |
| Male | 870 (51) | 207 (57) | 1414 (53) | 288 (53) | 1408 (52) | 326 (51) | |
| Female | 835 (49) | 150 (42) | 1274 (48) | 252 (47) | 1296 (48) | 321 (50) | |
| Age group |
|
|
|
|
|
| |
| 0 - 4 | 255 (15) | 13 (3) | 477 (18) | 20 (3) | 527 (19) | 6 (1) | |
| 5 - 14 | 707 (41) | 70 (19) | 891 (33) | 82 (15) | 988 (36) | 91 (14) | |
| 15 - 24 | 277 (17) | 101 (28) | 485 (18) | 128 (23) | 399 (15) | 168 (26) | |
| 25 - 34 | 152 (9) | 68 (19) | 296 (11) | 108 (20) | 280 (10) | 130 (20) | |
| 35 - 44 | 81 (47) | 33 (9) | 182 (7) | 49 (9) | 150 (5) | 85 (13) | |
| 45 - 54 | 82 (47) | 16 (4) | 133 (5) | 44 (8) | 129 (4) | 59 (9) | |
| 55 - 64 | 84 (49) | 24 (6) | 123 (4) | 52 (10) | 117 (4) | 42 (6) | |
| >65 | 67 (39) | 32 (9) | 101 (3) | 6 (1) | 117 (4) | 66 (10) | |